You Are Leaving Avistone's Website
You have selected a link that will take you to a site maintained by a third party. Avistone provides this link as a service to website visitors. Avistone is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit. Click 'Cancel' to return to Avistone's site or 'Continue' to proceed.
CONFERENCE REPORT
-
New Progress of the KUNPENG Study: Research Findings on Vebreltinib for Advanced NSCLC with MET Amplification Presented at the 2025 ESMO Asia Congress
Author：Prof. Yilong Wu et al.
Time：2025-12-06
2025
12-06
View Details
-
[ESMO ASIA 2025 Express] Avistone Unveils Groundbreaking Research Findings: New Evidence for Treating MET-Altered NSCLC Patients with EGFR-TKI Resistance
Author：Prof. Caicun Zhou et al.
Time：2025-12-05
2025
12-05
View Details
-
Avistone Presents Latest Clinical Studies of Andamertinib (PLB-1004) in Advanced NSCLC with EGFR Exon 20 Insertions at 2025 ESMO
Author：Yilong Wu, Jinji Yang et al.
Time：2025-10-18
2025
10-18
View Details
-
2025 WCLC: Vebreltinib of Avistone: Four Clinical Studies on MET Alterations were Presented as Poster Displays
Author：Jinji Yang et al.
Time：2025-09-08
2025
09-08
View Details
-
2025 ASCO：Vebreltinib plus PLB1004 in EGFR-mutated NSCLC with Acquired MET Amplification or Overexpression after Failure on EGFR-TKI Treatment: A Phase Ib/II Study
Author：Caicu Zhou et al.
Time：2025-05-31
2025
05-31
View Details
